Sionna Therapeutics (NASDAQ:SION) Director Bruce Booth Sells 606 Shares of Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Bruce Booth sold 606 shares of the company’s stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $29.95, for a total value of $18,149.70. Following the completion of the transaction, the director directly owned 771,762 shares of the company’s stock, valued at approximately $23,114,271.90. This represents a 0.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Bruce Booth also recently made the following trade(s):

• On Wednesday, October 15th, Bruce Booth sold 115,856 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.61, for a total value of $3,546,352.16.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.38, for a total value of $1,769,088.16.
• On Friday, October 10th, Bruce Booth sold 20,238 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.98, for a total value of $606,735.24.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total value of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total value of $5,990.00.
• On Tuesday, September 30th, Bruce Booth sold 12,388 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.06, for a total value of $372,383.28.
• On Monday, September 29th, Bruce Booth sold 66,105 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.09, for a total value of $1,989,099.45.

Sionna Therapeutics Price Performance

Shares of NASDAQ SION opened at $30.91 on Thursday. The stock has a fifty day simple moving average of $24.93 and a two-hundred day simple moving average of $18.21. Sionna Therapeutics, Inc. has a 1-year low of $7.26 and a 1-year high of $31.47.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.27.

Institutional Investors Weigh In On Sionna Therapeutics

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new stake in Sionna Therapeutics during the second quarter valued at about $31,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Sionna Therapeutics during the second quarter valued at about $45,000. Virtus Investment Advisers LLC purchased a new stake in Sionna Therapeutics during the second quarter valued at about $96,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Sionna Therapeutics during the second quarter valued at about $117,000. Finally, New York State Common Retirement Fund purchased a new stake in Sionna Therapeutics during the second quarter valued at about $118,000.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Weiss Ratings restated a “sell (d)” rating on shares of Sionna Therapeutics in a research report on Wednesday, October 8th. Royal Bank Of Canada assumed coverage on Sionna Therapeutics in a research report on Wednesday, September 3rd. They set a “sector perform” rating and a $22.00 target price on the stock. Raymond James Financial assumed coverage on Sionna Therapeutics in a research report on Tuesday, September 2nd. They set a “strong-buy” rating and a $45.00 target price on the stock. Jones Trading assumed coverage on Sionna Therapeutics in a research report on Monday, September 8th. They set a “buy” rating and a $46.00 target price on the stock. Finally, Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.